Key resources and tools to enable robust trial designs during the COVID-19 outbreak, as well as the latest information regarding ongoing trials
There are many questions surrounding COVID-19 trials that may vary across different settings. Are you considering conducting a trial? If so, then please let us know what you have planned and if you need any support. Are you looking for groups to collaborate with? Do you want to let others know you would like to be a site in a trial they are planning?
We want to support any team wanting to run a high-quality trial in different settings and especially in LMICs. We can help coordinate discussions and support your plans. We can also set up a forum for developing ideas and asking questions. Please get in touch and get involved!
Navigate intervention trials below
NEWS: International COVID-19 trial to restart with focus on immune responses
What Support is Available?
The European Medicines Agency (EMA) encourages developers of potential vaccines or treatments for novel coronavirus infection to contact EMA as soon as possible to discuss their strategy for evidence-generation, by emailing 2019-ncov@ema.europa.eu. The EMA can also provide medicine developers with scientific advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. Scientific advice is free of charge and can be fast-tracked for potential novel coronavirus treatments or vaccines.
Fundação Oswaldo Cruz (Fiocruz) has created a resource area highlighting important sources of information about the pandemic, to facilitate the circulation of knowledge and help the entire scientific community to keep abreast of the latest news about the disease.
